David J. Frost - Concepedia

Author

David J. Frost

Abbott Fund

Also Known As

D FROST, D Frost, D J Frost, D. FROST, D. Frost, D. J. FROST, D. J. Frost, D.J. Frost, DAVID FROST, DAVID J. FROST

164

Publications

5.5K

Citations

H-Index

118

Concepts

All Affiliations

Abbott Fund Abbott (United Kingdom)Unilever (Netherlands)Abbott (United States)Georgia Institute of Technology

About

David J. Frost is an author at Abbott Fund specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	1.9K
2	Natural Sciences	17	25	1.1K
3	Engineering	15	19	665
4	Health Sciences	3	3	172
5	Public Health	2	2	39

David J. Frost

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Cherrie K. Donawho, Yan Luo, Yanping Luo, Clinical Cancer Research	2007	762
Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation Le Wang, Keith W. Woods, Qun Li, Journal of Medicinal Chemistry Medicinal ChemistryDrug TargetingOncologyHeterocyclicStructure−activity Relationship	2002	420
A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria Loren G. Fong, David J. Frost, Margarita Meta, Science	2006	311
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi, Journal of Medicinal Chemistry	2008	264
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes, Clinical Cancer Research	2008	209
A Whole-Cell Candida albicans Assay for the Detection of Inhibitors towards Fungal Cell Wall Synthesis and Assembly. David J. Frost, Kim Brandt, David J. Cugier, The Journal of Antibiotics	1995	185
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i> Alex R. Shoemaker, Anatol Oleksijew, Joy Bauch, Cancer Research	2006	146
ABT-888 Confers Broad <i>In vivo</i> Activity in Combination with Temozolomide in Diverse Tumors Joann P. Palma, Yichun Wang, Luis E. Rodrı́guez, Clinical Cancer Research	2009	138
Synthesis and Biological Evaluation of 2-Indolyloxazolines as a New Class of Tubulin Polymerization Inhibitors. Discovery of A-289099 as an Orally Active Antitumor Agent Qun Li, Keith W. Woods, Akiyo Claiborne, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesTubulin Polymerization Inhibitors	2002	123
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Scott Ackler, Michael J. Mitten, Kelly Foster, Cancer Chemotherapy and Pharmacology Hematological MalignancyTumor BiologyBcl-2 Inhibitor Abt-263MedicineMalignant Blood Disorder	2010	120

Page 1